CD274 and neoplasm: Low dose Diosbulbin-B (DB) (12.5 μ M) activates tumor-intrinsic PD-L1/NLRP3 signaling pathway to restore the sensitivity of the cisplatin resistant GC (CR-GC) cells to cisplatin, the level of PD-L1 downregulates simultaneously in GC cells (74).